Table 1.

Demographic, Clinical and Procedural Characteristics of the Discovery and Validation Cohorts

	Discovery Cohort			Validation Cohort

Characteristics	Survived (n=835)	Died (n=183)	P^*	Survived (n=831)	Died (n=99)	P^*
Demographics
Age (years)	61 (11)	67 (10)	< 0.001	64 (10)	67 (10)	< 0.001
Gender (% female)	29	49	0.004	23	34	0.01
Medical history
Diabetes (%)	32	56	<0.001	30	33	0.43
Peripheral vascular disease (%)	14	25	0.008	11	23	< 0.001
Preoperative LVEF (%)	52 (13)	47 (15)	< 0.001	56 (14)	50 (17)	< 0.001
Procedural factors
CBP duration (min)	111 (55)	125 (50)	0.019	113 (37)	141 (70)	< 0.001
Intraoperative aprotinin (%)	8	16	<0.001	15	18	0.14
Number of grafts	3.16(0.9)	3.04(0.8)	0.025	2.25(1.2)	2.5(1.4)	0.38
IMA use (%)	93	92	0.57	97	93	0.06
Logistic EuroSCORE	3.3 [1.8–6.4]	6.3 [2.9–14.7]	< 0.001	3.2 [1.9–5.7]	6.1 [2.9–13.8]	< 0.001
Medications at hospital discharge
Aspirin (%)	93	91	0.2	91	94	0.38
Statin (%)	53	42	0.009	44	40	0.53
Beta-blocker (%)	87	74	<0.001	88	77	0.03
Year of surgery			0.84			0.7
Genotype
THBD rs1042579 (discovery cohort only)^a (%)			<0.001^#
CC	69	66
CT	28	25
TT	3	9
THBD rs3176123 (validation cohort only)^b (%)						0.019^#
GG				65	60
GT				31	29
TT				4	11

Values expressed as mean (SD), median [interquartile range], or as %.

Wilcoxon rank-sum (continuous variables); Pearson χ² (categorical variables).

Probability values refer to a univariate 2-degrees-of-freedom genotypic model. LVEF, left ventricular ejection fraction; CPB, cardiopulmonary bypass; THBD, thrombomodulin.

the minor allele frequency of rs1042579 in the discovery cohort was 0.17;

the minor allele frequency of rs3176123 in the validation cohort was 0.2.